Impact of hemodialysis therapy on anemia of chronic kidney disease: The potential mechanisms

Blood Purification

Volumn 32, Issue 3, 2011, Pages 210-219

  Bowry, Sudhir K ^a   Gatti, Emanuele ^a,b  

^a FRESENIUS MEDICAL CARE   (Germany)

^b DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

Anemia of chronic kidney disease; Online hemodiafiltration; Uremic toxins

Indexed keywords

ANTIANEMIC AGENT; IRON;

ANEMIA; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE; ERYTHROPOIESIS; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; IRON METABOLISM; LIFESPAN; ONLINE HEMODIAFILTRATION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; UREMIA;

ANEMIA; BONE MARROW; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; ERYTHROCYTES; ERYTHROPOIESIS; HUMANS; INFLAMMATION; IRON; KIDNEY DISEASES; RENAL DIALYSIS;

EID: 79960873908     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000329573     Document Type: Review

References (74)

1. Himmelfarb J, Ikizler TA: Hemodialysis. N Engl J Med 2010; 363: 1833-1845.
2. Meyer TW, Hostetter TH: Uremia. N Engl J Med 2007; 357: 1316-1325.
3. Vanholder R, van Laecke S, Glorieux G: What is new in uremic toxicity? Pediatr Nephrol 2008; 23: 1211-1221.
4. Bowry SK, Kuchinke-Kiehn U, Ronco C: The cardiovascular burden of the dialysis patient: the impact of dialysis technology. Contrib Nephrol 2005; 149: 230-239. (Pubitemid 43265020)
5. Cavalli A, Del Vecchio L, Manzoni C, Locatelli F: Hemodialysis: yesterday, today and tomorrow. Minerva Urol Nefrol 2010; 62: 1-11.
6. Locatelli F, Martin-Malo A, Hannedouche T, et al: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645-654.
7. Ronco C: Hemodiafiltration: evolution of a technique towards better dialysis care. Contrib Nephrol 2011; 168: 19-27.
8. Canaud B, Chenine L, Henriet D, Leray H: Online hemodiafiltration: a multipurpose therapy for improving quality of renal replacement therapy. Contrib Nephrol 2008; 161: 191-198.
9. Ledebo I: Convective dialysis therapies, current status and perspective. Ther Apher Dial 2005; 9: 223-227. (Pubitemid 41099504)
10. van der Weerd NC, Penne EL, van den Dorpel MA, et al: Haemodiafiltration: promise for the future? Nephrol Dial Transplant 2008; 23: 438-443. (Pubitemid 351767648)
11. Canaud B, Bragg-Gresham JL, Marshall M, et al: Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69: 2087-2093. (Pubitemid 43924275)
12. Jirka T, Cesare S, Di Benedetto A, et al: Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 70: 1524. (Pubitemid 44527327)
13. Penne EL, Blankestijn PJ, Bots ML, et al: Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch Convective Transport Study. Semin Dial 2005; 18: 47-51. (Pubitemid 40348276)
14. Locatelli F, Manzoni C, Cavalli A, Di Filippo S: Can convective therapies improve dialysis outcomes? Curr Opin Nephrol Hypertens 2009; 18: 476-480.
15. Panichi V, Tetta C: The biological response to online hemodiafiltration. Contrib Nephrol 2007; 158: 194-200.
16. Lankhorst CE, Wish JB: Anemia in renal disease: diagnosis and management. Blood Rev 2010; 24: 39-47.
17. Wish JB: The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int 2006; 70:S21-S25. (Pubitemid 44764123)
18. Kovesdy CP, Kantar-Zadeh K: Emerging challenges of anemia management in CKD. Adv Chronic Kidney Dis 2009; 16: 74-75.
19. Coyne DW: It's time to compare anemia management strategies in hemodialysis. Clin J Am Soc Nephrol 2010; 5: 740-742.
20. Ohno Y, Rege AB, Fisher JB, Barona J: Inhibitors of erythroid colony forming cells CFU-E and BFU-E in sera of azotemic patients with anemia of renal disease. J Lab Clin Med 1978; 92: 916-923. (Pubitemid 9090262)
21. Bonomini M, Sirolli V: Uremic toxicity and anemia. J Nephrol 2003; 16: 21-28.
22. Nolph KD: Comparison of continuous ambulatory peritoneal dialysis and hemodialysis. Kidney Int 1988; 33:S123-S131. (Pubitemid 18078154)
23. Mcdougall I: Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int 2001; 58: 67-72.
24. Yamada S, Kataoka H, Kobayashi H, Ono T, Minakuchi J, Kawano Y: Identification of an erythropoietic inhibitor from the dialysate collected in hemodialysis with PMMA membrane (BK-F). Contrib Nephrol 1999; 125: 159-172.
25. Ayli D, Ayli M, Azak A, et al: The effect of high-flux hemodialysis on renal anemia. J Nephrol 2004; 17: 701-706. (Pubitemid 40484584)
26. Bonforte G, Grillo P, Zerbi S, Surian M: Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume online prepared fluid. Blood Purif 2002; 20: 357-363. (Pubitemid 34920517)
27. Lin CL, Huang CC, Yu CC, et al: Improved iron utilisation and erythropoietin resistance by online haemodiafiltration. Blood Purif 2002; 20: 349-356.
28. Maduell F, del Pozo C, Garcia H, Sanchez L, Hdez-Jaras J, Albero MD, Calvo C, Torregrosa I, Navarro V: Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999; 14: 1202-1207. (Pubitemid 29209308)
29. Galli F, Beninati S, Benedetti S, et al: Polymeric protein-polyamine conjugates: a new class of uremic toxins affecting erythropoiesis. Kidney Int 2001; 59:S73-S76. (Pubitemid 32144074)
30. Lutton JD, Solangi KB, Ibraham NG, Goodman AI, Levere RD: Inhibition of erythropoiesis in chronic renal failure. The role of parathyroid hormone. Am J Kidney Dis 1984; 5: 380-384. (Pubitemid 14125552)
31. Hörl WH: The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004; 19:V2-V8. (Pubitemid 39214193)
32. Almeras C, Argiles A: The general picture of uremia. Semin Dial 2009; 22: 329-333.
33. Vaslaki L, Major L, Berta K, et al: On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif 2006; 24: 163-173. (Pubitemid 43259169)
34. Zehnder C, Gutzwiller J-P, Renggli K: Hemodiafiltration-a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999; 52: 152-159. (Pubitemid 29419469)
35. Lornroy W, De Meester J, Because I, Billiouw J-M, Van Malderen PA, Van Pottelberge M: Impact of convective flow on phosphorous removal in maintenance hemodialysis patients. J Renal Nutr 2006; 16: 47-53. (Pubitemid 43088755)
36. Garneata L: Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients? J Renal Nutr 2008; 18: 40-45. (Pubitemid 350251826)
37. Kalantar-Zadeh, Streja E, Miller JE, Nissenson AR: Intravenous versus erythropoiesisstimulating agents: friends or foes in treating chronic kidney disease anemia? Adv Chronic Kid Dis 2009; 16: 143-151.
38. Ganz T: Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 2006; 1: 29-35.
39. Babitt JL, Lin HY: Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726-741.
40. Zaritsky J, Young B, Gales B, et al: Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010; 5: 1010-1014.
41. Malyszko J, Malyszko JS, Kozminski P, Mysliwiec M: Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin. Renal Fail 2009; 31: 876-883.
42. Kruse A, Uehlinger DE, Gotch F, Kotanko P, Levin NW: Red blood cell lifespan, erythropoiesis and haemoglobin control. Contrib Nephrol 2008; 161: 247-254.
43. Pandolfi A, Di Pietro N, Sirolli V, et al: Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007; 213: 699-709. (Pubitemid 350058263)
44. Bonomini M, Ballone E, Di Stante S, et al: Removal of uraemic plasma factor(s) using different dialysis modalities reduces phosphatidylserine exposure in red blood cells. Nephrol Dial Transplant 2004; 19: 68-74. (Pubitemid 38072617)
45. Stenvinkel P: New insights on inflammation in chronic kidney disease-genetic and nongenetic factors. Nephrol Ther 2006; 2: 111-119. (Pubitemid 44160677)
46. Chawla LS, Krishnan M: Causes and consequences of inflammation on anemia management in haemodialysis patients. Hemodial Int 2009; 13: 222-234.
47. Allen DA, Breen C, Yaqoob MM, Macdougall IC: Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and IL-1. J Invest Med 1999; 47: 204-211. (Pubitemid 129576364)
48. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beerman NM, Struyvenberg A, Marx JJ: Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 1998; 13: 82-88. (Pubitemid 28033584)
49. Eleftheriadis T, Liaopoulos V, Antoniadi G, Kartsios C, Stefanidis I: The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial 2009; 22: 70-77.
50. De Francisco ALM, Stenvinkel P, Vaulot S: Inflammation and its impact on anemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. Nephrol Dial Transplant Plus 2009; 2:i18-i26.
51. Nangaku M, Eckardt KU: Pathogenesis of renal anemia. Semin Nephrol 2006; 26: 261-268. (Pubitemid 44722454)
52. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R: P-cresylsulfate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-596. (Pubitemid 46189906)
53. Piroddi M, Depunzio I, Calabrese V, et al: Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients. Amino Acids 2007; 32: 573-592. (Pubitemid 46790939)
54. Carracedo J, Merino A, Nogueras S, et al: On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: a prospective, crossover study. J Am Soc Nephrol 2006; 17: 2315-2321. (Pubitemid 44141923)
55. Panichi V, Rizza GM, Paoletti S, et al: Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008; 23: 2337-2343. (Pubitemid 351957592)
56. Schindler R: Inflammation and dialysate quality. Hemodial Int 2006; 10:S56-S59. (Pubitemid 43263311)
57. Lonnemann G: Chronic inflammation in hemodialysis: the role of contaminated dialysate. Blood Purif 2000; 18: 214-223. (Pubitemid 30619960)
58. European Best Practice Guideline for Haemodialysis Part 1. IV.1 Water treatment system. Nephrol Dial Transplant 2002; 17: 45-62.
59. Hsu P-Y, Lin C-L, Yu C-C, et al: Ultrapure dialysate improves iron utilisation and erythropoietin response in chronic hemodialysis patients-a prospective cross-over study. J Nephrol 2004; 17: 693-700. (Pubitemid 40484583)
60. Go I, Takemoto Y, Tsuchida K, Sugimura K, Nakatani T: The effect of ultrapure dialysate on improving renal anemia. Osaka City Med J 2007; 53: 17-23.
61. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G: Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant erythropoietin. Kidney Int 2003; 64: 572-578. (Pubitemid 36871928)
62. Toblli JE, Cao G, Oliveri L, Angerosa M: Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous compounds. Nephrol Dial Transplant 2010; 25: 3631-3640.
63. Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Vovic A: Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 2010; 29: 1-12.
64. Priyadarshi A, Shapiro JI: Erythropoietin resistance in the treatment of anemia of chronic renal failure. Semin Dial 2006; 19: 273-278. (Pubitemid 44091700)
65. Movilli E, Cancarini GC, Zani R, Camerini C, Sandrini M, Maiorca R: Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 2001; 16: 111-114. (Pubitemid 32051482)
66. Schiffl H: Prospective randomized crossover long-term comparison of online haemodiafiltration and ultrapure high-flux haemodialysis. Eur J Med Res 2007; 12: 26-33.
67. Kilpatrick RD, Critchlow CW, Fishbane S, et al: Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083.
68. Panichi V, Rosati A, Bigazzi R, et al: Anemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID Study. Nephrol Dial Transplant 2011, Epub ahead of print.
69. Pedrini LA, De Cristofaro V, Comelli M, et al: Long-term effects of high-efficiency online haemodiafiltration on uremic toxicity: a multi-centre prospective randomised study. Nephrol Dial Transplant 2011, Epub ahead of print.
70. Smith GCS, Pell JP: Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003; 327: 1459-1461. (Pubitemid 38045824)
71. Unger EF, Thomson AM, Blank MJ, Temple R: Erythropoiesis-stimulating agents-time for a reevaluation. N Engl J Med 2010; 21: 189-192.
72. Spiegel DM, Chertow GM: Lost without directions: lessons from the anemia debate and the Drive Study. Clin J Am Soc Nephrol 2009; 4: 1009-1010.
73. Locatelli F, Aljama P, Canaud B, et al: Target haemoglobin to aim for with erythropoiesisstimulating agents: a position statement by ERBP following publications of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Study. Nephrol Dial Transplant 2010; 25: 2846-2850.
74. Kotanko P, Levin NW: How can erythropoietin requirements be reduced in dialysis patients? Sem Dial 2006; 19: 363-364.